24 Participants Needed

Fat Tissue Injection vs Corticosteroid Injection for Shoulder Pain in Spinal Cord Injury

(MFAT-SCI Trial)

GA
NH
Trevor A. Dyson-Hudson, M.D. profile photo
Overseen ByTrevor A. Dyson-Hudson, M.D.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Prior Safety DataThis treatment has passed at least one previous human trial

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial uses a patient's own processed fat to treat shoulder pain in people with spinal cord injuries who haven't improved with other treatments. The fat helps heal the shoulder by providing cushioning and regenerative cells.

Will I have to stop taking my current medications?

The trial protocol does not specify whether you need to stop taking your current medications. However, if you are currently taking anti-coagulants or have had a glucocorticoid injection in the past 4 weeks, you may not be eligible to participate.

Is fat tissue injection safe for treating shoulder pain in spinal cord injury?

Research on fat tissue injections, specifically using adipose-derived stem cells, suggests they are generally safe in humans, as seen in a study where a patient with spinal cord injury tolerated the procedure well without severe adverse events.12345

How does the treatment Lipogems differ from other treatments for shoulder pain in spinal cord injury?

Lipogems is unique because it uses fat tissue injections, which can provide a source of progenitor cells and deliver therapeutic genes, potentially reducing inflammation and promoting tissue repair. This approach is different from traditional corticosteroid injections, which primarily focus on reducing inflammation without the regenerative potential of fat tissue.34567

What data supports the effectiveness of the treatment for shoulder pain in spinal cord injury patients?

The research shows that corticosteroid injections, which are part of the treatment being studied, are confirmed therapies for shoulder pain in spinal cord injury patients. Additionally, micro-fragmented adipose tissue injections have been explored for their safety and potential benefits in treating shoulder pain in similar populations.89101112

Are You a Good Fit for This Trial?

This trial is for adults aged 18-70 with chronic shoulder pain due to rotator cuff disease, who have had a spinal cord injury between C6 and L5 at least one year ago. Participants must be wheelchair users (over 40 hours/week) and have not found relief from pain after six months of conservative treatment. They cannot join if they have systemic disorders like diabetes or rheumatoid arthritis, previous adipose tissue injections, contraindications like infection or coagulopathy, are pregnant, or recently had corticosteroid injections.

Inclusion Criteria

I have had shoulder pain for over 6 months despite treatment.
I have shoulder pain confirmed by an ultrasound to be due to rotator cuff issues.
My shoulder pain has been at least a 4 out of 10 in the past week.
See 3 more

Exclusion Criteria

I have received MFAT treatment before.
I have a chronic condition like diabetes or rheumatoid arthritis.
I do not have any health conditions that could affect the study's results.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive either a micro-fragmented adipose tissue injection or a corticosteroid injection under ultrasound guidance

1 day
1 visit (in-person)

Rehabilitation

Participants follow a standardized stretching protocol for 4 weeks followed by a formal strengthening program

4 weeks

Follow-up

Participants are monitored for adverse events and changes in shoulder pain intensity, with assessments at 1, 2, 3, and 6 months post-treatment

6 months
4 visits (in-person)

What Are the Treatments Tested in This Trial?

Interventions

  • Dexamethasone
  • Lipogems
Trial Overview The study compares the effectiveness of Lipogems®, an injection of micro-fragmented adipose tissue guided by ultrasound, against dexamethasone (a corticosteroid) for relieving chronic shoulder pain in wheelchair users with spinal cord injuries. The goal is to see if Lipogems® can provide better long-term relief without the potential tendon damage associated with repeated steroid use.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Active Control
Group I: Micro-Fragmented Adipose TissueExperimental Treatment1 Intervention
Participants will receive a single injection of micro-fragmented adipose tissue into the lesion (e.g. tear, subacromial bursa, glenohumeral joint, acromioclavicular joint) under ultrasound guidance using an 18 gauge x 3.5 inch needle.
Group II: CorticosteroidActive Control1 Intervention
Participants will receive a corticosteroid injection (BMS, Kenacort-A 40 mg \[triamcinolone acetonide\]) into the subacromial space under direct ultrasound guidance by means of a 5-mL syringe with a 22-guage needle.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Kessler Foundation

Lead Sponsor

Trials
190
Recruited
11,300+

Published Research Related to This Trial

In a pilot study involving 10 wheelchair users with chronic shoulder pain due to rotator cuff disease, ultrasound-guided injections of micro-fragmented adipose tissue (MFAT) showed no significant adverse events, indicating a good safety profile.
Significant reductions in pain scores were observed at 6 and 12 months post-injection, with 77.8% of participants experiencing clinically meaningful improvements, suggesting that MFAT injections may be an effective treatment option for refractory shoulder pain in this population.
A pilot study to evaluate micro-fragmented adipose tissue injection under ultrasound guidance for the treatment of refractory rotator cuff disease in wheelchair users with spinal cord injury.Hogaboom, N., Malanga, G., Cherian, C., et al.[2022]
The CELLTOP study is investigating the safety and efficacy of intrathecal injections of autologous adipose tissue-derived mesenchymal stem cells (AD-MSCs) in patients with spinal cord injury, with initial results showing that the first patient tolerated the procedure well without severe adverse events.
After receiving 100 million AD-MSCs, the patient demonstrated meaningful neurological improvement over 18 months, suggesting that this regenerative approach may offer potential benefits for restoring function in spinal cord injury cases.
CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury.Bydon, M., Dietz, AB., Goncalves, S., et al.[2020]

Citations

Ultrasound-guided versus blind subacromial bursa corticosteroid injection for paraplegic spinal cord injury patients with rotator cuff tendinopathy: a randomized, single-blind clinical trial. [2022]
Transfer Technique Is Associated With Shoulder Pain and Pathology in People With Spinal Cord Injury: A Cross-Sectional Investigation. [2017]
A pilot study to evaluate micro-fragmented adipose tissue injection under ultrasound guidance for the treatment of refractory rotator cuff disease in wheelchair users with spinal cord injury. [2022]
Rotator cuff repairs in individuals with paraplegia. [2019]
Ultrasound-guided platelet-rich plasma injection for the treatment of recalcitrant rotator cuff disease in wheelchair users with spinal cord injury: A pilot study. [2022]
CELLTOP Clinical Trial: First Report From a Phase 1 Trial of Autologous Adipose Tissue-Derived Mesenchymal Stem Cells in the Treatment of Paralysis Due to Traumatic Spinal Cord Injury. [2020]
Efficacy of methylprednisolone therapy for the injured rat spinal cord. [2022]
Gene-activated fat grafts for the repair of spinal cord injury: a pilot study. [2018]
Human Adipose-Derived Stem Cells Combined with Nano-Hydrogel Promote Functional Recovery after Spinal Cord Injury in Rats. [2022]
Neuroprotection, Recovery of Function and Endogenous Neurogenesis in Traumatic Spinal Cord Injury Following Transplantation of Activated Adipose Tissue. [2020]
11.United Statespubmed.ncbi.nlm.nih.gov
Technical aspects of spinal cord injections for cell transplantation. Clinical and translational considerations. [2011]
12.United Statespubmed.ncbi.nlm.nih.gov
Bone marrow stem cells and polymer hydrogels--two strategies for spinal cord injury repair. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security